Andere talen Roivant Sciences Ltd.

Aandelen

ROIV

BMG762791017

Farmaceutische producten

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 05-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
20,97 ^USD	-0,99%		+0,77%	+77,26%

24/11	Roivant Sciences: Insider Verkoopt Aandelen ter Waarde van $26.304.500, Blijkt uit Recente SEC-Melding	MT
18/11	Roivant Sciences Ltd. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 05:00 PM

Andere talen

Roivant Sciences Insider Sold Shares Worth $26,304,500, According to a Recent SEC Filing	24/11
Roivant Sciences Insider Sold Shares Worth $37,939,112, According to a Recent SEC Filing	17/11
Markets Seek Direction	11/11
Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…	11/11
Roivant Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	10/11
Roivant Sciences' Fiscal Q2 Net Loss Narrows, Revenue Falls	10/11
Tranche Update on Roivant Sciences Ltd.'s Equity Buyback Plan announced on August 11, 2025.	10/11
Stocks Gain Pre-Bell as Senate Moves One Step Further to End Government Shutdown	10/11
Biopharma Roivant's Q2 income from operations misses	10/11
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q2 Revenue $1.6M, vs. FactSet Est of $5.6M	10/11
Earnings Flash (ROIV) Roivant Sciences Posts Fiscal Q2 Net Loss $0.17 a Share, vs. FactSet Est of $0.33 Loss	10/11
Earnings Flash (ROIV) Roivant Sciences Ltd. Reports Q2 Revenue $1.6M, vs. FactSet Est of $5.6M	10/11
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update	10/11
Roivant Sciences Insider Sold Shares Worth $4,044,000, According to a Recent SEC Filing	10/11
Vor Bio Appoints Jeremy Sokolove as Chief Medical Officer	03/11
Roivant to report financial results for the second quarter ended September 30, 2025, and provide business update on Monday, November 10, 2025	27/10
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025	27/10
Roivant Sciences Insider Sold Shares Worth $14,467,502, According to a Recent SEC Filing	20/10
Roivant Sciences Insider Sold Shares Worth $10,781,813, According to a Recent SEC Filing	09/10
Roivant Sciences files for mixed shelf offering - SEC filing	03/10
Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings	22/09
Analyst recommendations: Autozone, Crowdstrike, Deere & Company, Micron Technology, MongoDB...	18/09
Roivant and Priovant's drug for rare skin, muscle disease shows promise in trial	17/09
Roivant and Priovant announce positive phase 3 Valor study results for brepocitinib in 52-week placebo-controlled trial in dermatomyositis (Dm)	17/09
Sector Update: Health Care Stocks Rise Premarket Wednesday	17/09

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Roivant Sciences Ltd.

Aandelen

ROIV

BMG762791017

Farmaceutische producten

Andere talen

Filters